Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.15
48.84
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dizal Jiangsu Pharmaceutical Co Ltd
Total Liabilities & Equity
Dizal Jiangsu Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
|
Total Liabilities & Equity
¥1.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities & Equity
¥41.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Liabilities & Equity
¥20.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities & Equity
¥15.7B
|
CAGR 3-Years
65%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities & Equity
¥54.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
38%
|
CAGR 10-Years
36%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Liabilities & Equity
¥6.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
Dizal Jiangsu Pharmaceutical Co Ltd
Glance View
In the heart of China's vibrant pharmaceutical landscape lies Dizal Jiangsu Pharmaceutical Co Ltd, a dynamic company at the forefront of innovative drug development. Founded as a joint venture with a vision to bridge unmet medical needs, Dizal focuses primarily on oncology and immunology. This firm thrives on its strong pipeline of next-generation therapies, nurtured by a robust research and development arm. Collaborating with global biotech entities, it leverages cutting-edge technologies and deep scientific acumen to create breakthrough biologic and small molecule drugs that hold the potential to transform patient outcomes. Dizal’s research hubs are bustling with expert scientists dedicated to translating scientific discoveries into tangible therapies, positioning the company as a significant player in the biopharmaceutical sector. Dizal makes its money through a well-orchestrated stream of activities emphasizing strategic partnerships, intellectual property licensing, and product sales. By forging alliances with industry giants for co-development and commercialization, the company ensures a wider reach and impactful roll-out of its products. Additionally, the progressive monetization strategy of awarding patents and licenses in conjunction with its proprietary compounds enables a steady revenue inflow. This symbiotic model not only empowers Dizal to fund further innovative research but also reinforces its stature within the competitive arena of drug development. As healthcare demands continuously evolve, Dizal’s revenue generation strategies remain agile, marrying scientific ingenuity with strategic foresight.
See Also
What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
1.5B
CNY
Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 1.5B CNY.
What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
19%
Over the last year, the Total Liabilities & Equity growth was -28%. The average annual Total Liabilities & Equity growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 8% over the past three years , 19% over the past five years .
You don't have any saved screeners yet
